Verbatim response from ChatGPT
Short answer
- The FDA has moved to stop many pharmacies and clinics from selling compounded versions of GLP‑1 drugs (like semaglutide and tirzepatide) that are essentially copies of FDA‑approved brand products.
- FDA‑approved manufacturers (Novo Nordisk, Eli Lilly, etc.) remain the lawful source of approved GLP‑1 products (Ozempic, Wegovy, Rybelsus; Mounjaro, Zepbound, etc.).
- Compounding is still legal in limited, specific situations: patient‑specific prescriptions from state‑licensed 503A pharmacies or product made by FDA‑registered 503B outsourcing facilities that follow the law — but compounding exact copies of approved GLP‑1 biologics is what FDA has been enforcing against.
What happened (brief timeline and why)
- Demand for GLP‑1 drugs for weight loss and diabetes surged in 2022–2023. Many compounding pharmacies began offering injectable “semaglutide” or “tirzepatide” formulations — often online or on a national basis.
- Manufacturers (Novo Nordisk, Eli Lilly) and the FDA raised safety, quality, intellectual‑property and regulatory concerns: compounded products may vary in dose/potency, sterility and purity, and some are effectively copies of FDA‑approved drugs or biologics.
- From 2023 into 2024 the FDA issued statements and warning/enforcement actions against some pharmacies and outsourcing facilities that promoted or distributed compounded GLP‑1 products in ways the agency judged illegal (for example, making non–patient‑specific copies, shipping interstate from 503A pharmacies, or compounding biologics that shouldn’t be compounded). State boards of pharmacy also took actions in some cases.
Legal framework (why some compounding is allowed but much is not)
- 503A pharmacies (traditional state‑licensed compounding) may legally compound only when a licensed practitioner prescribes for a specific patient and when the compound is not essentially a copy of an FDA‑approved drug. Many compounded GLP‑1 offerings did not meet this standard.
- 503B outsourcing facilities can produce larger quantities for hospitals/clinics and must register with FDA and follow stricter quality rules — but they still cannot legally market copies of approved biologics or violate other FDA rules.
- The FDA has said biologic/complex peptide products raise special concerns; many GLP‑1 drugs are peptides/biologics, which makes compounding them more legally and technically fraught.
Who is still operating legally
- FDA‑approved manufacturers and their authorized distribution channels (e.g., Novo Nordisk and Eli Lilly products sold through pharmacies and clinics) — these are the reliable legal sources.
- State‑licensed compounding pharmacies operating only on a patient‑specific prescription basis and following state and federal law may legally make certain compounded medications, but compounding an “essential copy” of an FDA‑approved GLP‑1 product is likely to attract enforcement.
- FDA‑registered 503B outsourcing facilities that are compliant with FDA rules and that do not make illegal copies can operate legally; they must be on the FDA outsourcing facility list and should have good quality records.
Practical advice if you’re considering a compounded GLP‑1
- Prefer FDA‑approved products (Wegovy/Ozempic for semaglutide; Mounjaro/Zepbound for tirzepatide) because they have established dosing, safety data, and manufacturing controls. Manufacturers: Novo Nordisk (semaglutide brands), Eli Lilly (tirzepatide brands).
- If a compounding option is being suggested, ask the pharmacy for: evidence they are a registered 503B or a state‑licensed 503A doing only patient‑specific compounding; PCAB or other accreditation; Certificates of Analysis (potency/sterility); where they source the active pharmaceutical ingredient. If they can’t or won’t provide these, be very cautious.
- Check the FDA website for current warning letters and the list of registered outsourcing facilities; check your state Board of Pharmacy for any enforcement actions.
- For legal or medical certainty about a particular pharmacy or practice, consult your provider, your state board of pharmacy, or a lawyer with health‑regulatory experience.
If you want, I can:
- Look up current FDA warning letters and the outsourcing facility list for any specific pharmacy or company you name (I can show you how to find them), or
- Point you to the FDA pages and state board resources to verify whether a particular compounding pharmacy is currently in compliance.